Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cidara Therapeutics ( (CDTX) ) has issued an update.
On June 24, 2025, Cidara Therapeutics announced the suspension and termination of its ATM Prospectus related to common stock sales under its agreement with Jefferies LLC. The company will halt stock sales until a new prospectus is filed, though the sales agreement itself remains active, indicating a strategic pause rather than a complete cessation of stock activities.
The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.
Spark’s Take on CDTX Stock
According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.
Cidara Therapeutics’ stock score is primarily hindered by its financial performance, marked by substantial losses and reliance on external financing. However, strong technical indicators and positive corporate events provide some optimism for future growth. The earnings call and valuation concerns, such as a negative P/E ratio, further temper the overall score.
To see Spark’s full report on CDTX stock, click here.
More about Cidara Therapeutics
Cidara Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of anti-infectives and immunotherapies.
Average Trading Volume: 275,533
Technical Sentiment Signal: Hold
Current Market Cap: $272.6M
See more insights into CDTX stock on TipRanks’ Stock Analysis page.